Gypenoside XLIX loaded nanoparticles targeting therapy for renal fibrosis and its mechanism

• DOI: 10.1016/j.ejphar.2021.174501
• Publication Date: 2021-09-13T05:33:14Z
• Authors: Qixia Liu; Xiaohui Chen; Min Kan; Jing Yang; Qian Gong; Rui Jin; Yulong Dai; Juan Jin; Hongmei Zang
• Keywords: Male; 0301 basic medicine; Saponins; Fibrosis; Cell Line; Specific Pathogen-Free Organisms; 3. Good health; Disease Models, Animal; Mice; 03 medical and health sciences; Kidney Tubules; Transforming Growth Factor beta; Gene Knockdown Techniques; Animals; Humans; Smad3 Protein; Renal Insufficiency, Chronic; Nanoparticle Drug Delivery System; Drugs, Chinese Herbal; Signal Transduction

Renal fibrosis is the main pathological feature of the occurrence and development of chronic nephropathy. At present, there is no effective treatment, except for renal transplantation and dialysis. Previous studies have shown that nano-preparations can be used as a therapeutic tool to target organs. In this study, we studied the therapeutic effect and mechanism of Chinese medicine monomer Gypenoside (Gyp) XLIX on renal fibrosis and explored the targeting and therapeutic effects of polylactic acid-co-glycoside (PLGA)-Gyp XLIX nanoparticles in unilateral ureteral occlusion (UUO) kidney. Gyp XLIX and PLGA-Gyp XLIX nanoparticles were used to treat UUO mice and Human renal tubular epithelial (HK2) cells stimulated by transforming growth factor-β (TGF-β). Histopathological and molecular biological techniques were used to detect the expression of type I collagen and alpha-smooth muscle actin (α-SMA). To investigate the in vivo targeting of PLGA nanoparticles, they were loaded with 1,1-dioctadecyl-3,3,3,3-tetramethylindotricarbocyanine iodide and injected into UUO mice. We evaluated the effect of Gyp XLIX nanoparticles on TGF-β/Smad3 pathway, a central driver for renal fibrosis in Smad-deficient HK2 cells. Fluorescence imaging showed that the PLGA nanoparticles around 120 nm could be targeted to the UUO kidney. Compared with Gyp XLIX, PLGA-Gyp XLIX nanoparticles could effectively inhibit renal fibrosis and reduce collagen deposition and reduce renal tubular necrosis. Gyp XLIX decreased the phosphorylation of Smad3, but could not further reduce the levels of type I collagen and α-SMA in Smad-deficient cells. This study opens a promising way for targeted drug treatment of renal fibrosis.